Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 12/20 | 1.00 |
| ▸ | PTPN2 | P17706 | 4/20 | 1.00 |
| ▸ | F3 | P13726 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | USP7 | Q93009 | 3/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 3/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 1.00 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 1.00 |
| ▸ | PSMA7 | O14818 | 2/20 | 1.00 |
| ▸ | PLA2G1B | P04054 | 2/20 | 1.00 |
| ▸ | PTPRC | P08575 | 2/20 | 1.00 |
| ▸ | PTPRF | P10586 | 2/20 | 1.00 |
| ▸ | PSMB1 | P20618 | 2/20 | 1.00 |
| ▸ | CES1 | P23141 | 2/20 | 1.00 |
| ▸ | ACP1 | P24666 | 2/20 | 1.00 |
| ▸ | PSMA1 | P25786 | 2/20 | 1.00 |
| ▸ | PSMA2 | P25787 | 2/20 | 1.00 |
| ▸ | PSMA3 | P25788 | 2/20 | 1.00 |
| ▸ | PSMA4 | P25789 | 2/20 | 1.00 |
| ▸ | PSMB8 | P28062 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oleanolic_Acid SCHEMBL15714063 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2F3POLBUSP7 | |
| Oleanolic_Acid SCHEMBL12337275 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2F3POLBUSP7 | |
| Oleanolic_Acid SCHEMBL18420569 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2F3POLBUSP7 | |
| Oleanolic_Acid SCHEMBL13425080 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2F3POLBUSP7 | |
| Oleanolic_Acid SCHEMBL13395360 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2F3POLBUSP7 | |
| Oleanolic_Acid SCHEMBL16153016 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2F3POLBUSP7 | |
| Oleanolic_Acid SCHEMBL24916648 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2F3POLBUSP7 | |
| Oleanolic_Acid SCHEMBL21892159 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2F3POLBUSP7 | |
| Oleanolic_Acid SCHEMBL22009261 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2F3POLBUSP7 | |
| Oleanolic_Acid SCHEMBL20904290 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2F3POLBUSP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021202103-A2 | METHOD AND COMPOSITIONS FOR TREATING CORONAVIRUS INFECTION | PHOENIX BIOTECHNOLOGY, INC. (US) | 2021-10-07 | — | — | WO | claimed |
| EP-2260851-A1 | USE OF PENTACYCLIC TRITERPENE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOUND INTENDED FOR THE TREATMENT OF MULTIPLE SCLEROSIS | Consejo Superior De Investigaciones Científicas (ES) | 2010-12-15 | — | — | EP | claimed |
| US-20260083753-A1 | Compositions for the Treatment of Metabolic Syndrome and Other Metabolic Disorders, and Methods of Manufacture | FLORIDA RES GROUP LLC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4009981-A1 | METHOD AND COMPOSITIONS FOR TREATING CORONAVIRUS INFECTION | Phoenix Biotechnology, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
| WO-2021202103-A2 | METHOD AND COMPOSITIONS FOR TREATING CORONAVIRUS INFECTION | PHOENIX BIOTECHNOLOGY, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021201903-A1 | METHOD AND COMPOSITIONS FOR TREATING CORONAVIRUS INFECTION | PHOENIX BIOTECHNOLOGY, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2020242752-A1 | METHOD AND COMPOSITIONS FOR TREATING HTLV-1 VIRUS INFECTION | PHOENIX BIOTECHNOLOGY, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| EP-2642859-A2 | METHOD OF TREATING NEUROLOGICAL CONDITIONS WITH EXTRACT OF NERIUM SPECIES OR THEVETIA SPECIES | Phoenix Biotechnology, Inc. (US) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012071152-A2 | METHOD OF TREATING NEUROLOGICAL CONDITIONS WITH EXTRACT OF NERIUM SPECIES OR THEVETIA SPECIES | PHOENIX BIOTECHNOLOGY, INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| EP-2431041-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CARDIOVASCULAR DISORDER AND USE THEREOF | Chengdu Kanghong Pharmaceutical Co., Ltd. (CN) | 2012-03-21 | — | — | EP | disclosed |
| EP-2260851-A1 | USE OF PENTACYCLIC TRITERPENE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOUND INTENDED FOR THE TREATMENT OF MULTIPLE SCLEROSIS | Consejo Superior De Investigaciones Científicas (ES) | 2010-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083753-A1 | Compositions for the Treatment of Metabolic Syndrome and Other Metabolic Disorders, and Methods of Manufacture | SLC2A4, NPC1L1, SLC2A3 | PTPN1 3677/4885PTPN2 3914/4885F3 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.